This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athlete’s foot (Tinea pedis), and key players active within these indications.
Both of these indications are fungal infections primarily affecting the feet. Onychomycosis affects the nails, whereas athlete’s foot affects the skin under the feet and between the toes. Common symptoms include discomfort, itchiness, and - in the case of onychomycosis - discoloured and disfigured nails. Combined, these infections affect around 25% of the adult population.
There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology. There are a total of 25 products in development for both indications, by 24 companies.